Nutriband Inc. joins multiple Russell indexes, reflecting its market growth and focus on developing its AVERSA abuse-deterrent technology.
Quiver AI Summary
Nutriband Inc. announced its inclusion in multiple Russell indexes, including the Russell Microcap and Russell 3000E indexes, as part of the 2025 reconstitution. This recognition reflects the company's growth focus and its efforts to enhance shareholder value, particularly concerning its AVERSA fentanyl patch technology aimed at deterring drug abuse. CEO Gareth Sheridan highlighted the potential sales of AVERSA Fentanyl, estimated between $80 million and $200 million annually, showcasing the importance of their innovation in providing safer medications. FTSE Russell, which oversees these indexes, emphasized the need to adapt the indexes to accurately represent the evolving US economy and mentioned a shift to semi-annual reconstitutions starting in 2026 to maintain relevance. Nutriband continues to develop transdermal pharmaceutical products designed to mitigate the risks associated with drugs that have abuse potential.
Potential Positives
- Nutriband Inc. has been added to multiple prominent Russell Indexes, which enhances its visibility and credibility among investors and institutions.
- The membership in the Russell 3000E and other indexes may lead to increased investment interest, potentially boosting the company's stock performance.
- The company's lead product, the AVERSA fentanyl patch, is positioned to address a significant market need, with potential annual sales ranging from $80 million to $200 million.
Potential Negatives
- The press release emphasizes dependence on forward-looking statements, indicating significant uncertainty regarding the company's future performance and product development.
- There are inherent risks highlighted related to obtaining necessary approvals and regulatory compliance, which could hinder product commercialization.
FAQ
What indexes has Nutriband Inc. joined?
Nutriband Inc. has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes.
What is the potential market for AVERSA Fentanyl?
The AVERSA Fentanyl product has the potential to reach peak annual US sales of $80 million to $200 million.
What is Nutriband's core technology focus?
Nutriband focuses on developing abuse-deterrent transdermal technology for pharmaceutical products, specifically for fentanyl patches.
Who is FTSE Russell?
FTSE Russell is a global index provider that offers benchmarking and data solutions for investors worldwide.
What are forward-looking statements in Nutriband’s press release?
Forward-looking statements include predictions and expectations regarding future events or outcomes related to company performance and product development.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTRB Hedge Fund Activity
We have seen 8 institutional investors add shares of $NTRB stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 74,437 shares (+59.7%) to their portfolio in Q1 2025, for an estimated $456,298
- FARTHER FINANCE ADVISORS, LLC removed 16,014 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $75,425
- AVANTAX ADVISORY SERVICES, INC. removed 13,647 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $83,656
- NORTHERN TRUST CORP added 11,482 shares (+inf%) to their portfolio in Q1 2025, for an estimated $70,384
- ATRIA WEALTH SOLUTIONS, INC. removed 10,934 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $51,499
- HRT FINANCIAL LP removed 10,662 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $50,218
- CITIGROUP INC added 10,209 shares (+inf%) to their portfolio in Q1 2025, for an estimated $62,581
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NTRB Analyst Ratings
Wall Street analysts have issued reports on $NTRB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Noble Capital Markets issued a "Outperform" rating on 01/22/2025
To track analyst ratings and price targets for $NTRB, check out Quiver Quantitative's $NTRB forecast page.
Full Release
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“Being added to the four Russell indexes is a great honor for us as a company as we continue to strive towards building shareholder value and progressing the development of our AVERSA pipeline and in particular AVERSA Fentanyl which has the potential to reach peak annual US sales of $80 million to $200 million. We believe our addition now reflects a market focus on us as a company and the momentum we are building to revolutionize the safety profile of easily abused medications while making these medications available to those in need as a result,” said Gareth Sheridan, CEO of Nutriband Inc.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell’s US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider.
Fiona Bassett, CEO of FTSE Russell, An LSEG business, comments:
“The Russell indexes have continuously adapted to the evolving dynamic US economy, and it’s crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.”
For more information on the Russell Microcap ® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com . Any material contained in or derived from the Company's websites or any other website is not part of this press release.
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell .
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information :
Nutriband Inc.
Phone: 407-377-6695
Email:
[email protected]
SOURCE: Nutriband Inc.